Biomet and Zimmer on integration plans; Cleveland Clinic ditches Apple for Microsoft;

@FierceMedDev: China patent will open Asia's door to Biocept's cancer Dx tests. FierceDiagnostics story | Follow @FierceMedDev

@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. More | Follow @MichaelGFierce

@VarunSaxena2: Treasury's crackdown on inversion could scupper Medtronic-Covidien deal. More | Follow @VarunSaxena2

@EmilyWFierce: Women more likely to skip prenatal testing if they have all the facts at hand, according to new study. More from NPR | Follow @EmilyWFierce

> To consummate their $13 billion merger, orthopedic companies Zimmer ($ZMH) and Biomet are in the midst of a series of integration summits to deal with necessary practical and strategic changes. Story

> The Cleveland Clinic temporarily jumped ship from Apple ($AAPL) to Microsoft ($MSFT). The clinic is using Microsoft's HealthVault to monitor remote or at-risk patients while Apple figures out bugs in its HealthKit platform. More

> Cynosure, a company focused on laser and light-based aesthetic treatments for noninvasive and minimally invasive applications, received FDA clearance to market its PicoSure device to treat wrinkles. It's already FDA-cleared for tattoo and benign pigmented lesion removal. Release

> Therapeutic device company Aethlon Medical announced a partnership with Qualtran to expand human clinical studies of Hemopurifier therapy to include patients suffering from dengue virus. Release

Biotech News

@FierceBiotech: Lipocine's low-T drug hits the mark in Phase III. Now it has to sway the FDA. Article | Follow @FierceBiotech

@JohnCFierce: Ahead of a split, Baxter strikes a $970M deal for Merrimack's lead cancer drug. News | Follow @JohnCFierce

@DamianFierce: But how will the $MACK deal affect the coming biotech softball playoffs? More from The Boston Globe | Follow @DamianFierce

> Waksal's back: Once-jailed biotech chief plots an IPO for his latest play. News

> Novartis-partnered Eureka rounds up $21M round for immuno-oncology drug research. Story

> Gilead heads to FDA after wrapping a PhIII HIV combo drug program. Item

> Bristol-Myers plots a 2,500-worker campus in New Jersey. Article

Pharma News

@FiercePharma: Man gets 25 years for violent last-mile robberies. FiercePharmaManufacturing story | Follow @FiercePharma

@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. More from FiercePharmaManufacturing | Follow @EricPFierce

> GlaxoSmithKline soon to name RBS chair Hampton as next chairman. Report

> Oh, what a tangled web of pharma M&A, starring Pfizer, Actavis, Allergan and Salix. Story

> Ackman threatens Allergan with lawsuit if Salix deal is sealed. Article

Drug Delivery News

> FDA moves aggressively on low-T drugs, but replacement pill still aims to enter market. Item

> Purdue team recreates tumor microenvironment to study cancer nanomed delivery. Report

> Novaliq's cyclosporin drop for dry eyes boasts PhI success. Story

> Titan Pharma trial of implant for addicts on track. Article

> English researchers fuse biologics to antibodies to treat rheumatoid arthritis. More

Diagnostics News

> NuView, Otsuka Pharmaceutical establish cancer biomarker licensing deal. News

> ImaginAb envisions in vivo molecular imaging tech as treatment assessment tool. Report

> Sequenom keeps prenatal Dx competition running with new positive data. Article

> T2 Biosystems gains FDA signoff for time-saving Candida Dx. Story

> U.K., Italy team push for regular Dx testing of prostate cancer patients under treatment. More

Pharma Marketing News

> Celgene's Otezla nabs psoriasis approval, launching next-gen showdown. Report

> J&J 'disappointed' U.K. watchdogs nixed Olysio-Sovaldi hep C combo. What next? More

> CNBC: Actavis swoops in on Allergan for Salix buyout talks. Item

> Can copay coupons be kickbacks? HHS says yes. More

> Bayer goes Glamour-ous with Girls star for new IUD campaign. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.